ARAY
$4.36
Accuray
($.18)
(3.96%)
ARAY
Earnings Whisper ®
N/A
2nd Quarter December 2020
Consensus:  ($0.01)
Revenue:  $88.80 Mil
Thursday
Jan 28
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ARAY reports earnings?
Beat
Meet
Miss

Where is ARAY's stock price going from here?
Up
Flat
Down
Stock chart of ARAY
Analysts
Summary of analysts' recommendations for ARAY
Score
Grade
Pivots
Resistance
$4.98
$4.81
$4.58

$4.41

Support
$4.18
$4.01
$3.78
Tweet
Growth
Description
ACCURAY INCORPORATED based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 130 systems have been installed in leading hospitals in the Americas, Europe and Asia.
Peers
StrykerBoston ScientificBaxter InternationalBecton, DickinsonAbbottWatersIntegra LifeSciences Holdings3MCardiovascular SystemsTeleflex